Over the last two decades, several studies have questioned the traditional viewing of septic shock as a hyperdynamic process, with preserved myocardial function and decreased peripheral resistance. Up to 60% of septic patients have left and/or right systolic dysfunction, regardless of the presence of baseline heart disease. The diagnostic methods of sepsis-induced myocardial dysfunction, as well as to what extent it conditions in response to treatment, remains a topic of debate.
This Research Topic aims to provide clinicians and researchers an overview on how to consider the presence of myocardial dysfunction in the management of septic patients, through diagnostic assessment and prognostic stratification. It is for this reason, all article types are encouraged.
Sub-topics include, but are not limited to:
1) A thorough evaluation on the role of biomarkers, ultrasound, and other imaging modalities in the diagnosis of sepsis-induced myocardial dysfunction.
2) To evaluate how the presence of sepsis-induced myocardial dysfunction affects the response to the fluid challenge and to vasoactive medications.
3) The use of Dobutamine or other novel inotropes for treatment options in sepsis-induced myocardial dysfunction.
4) Prognostic values of sepsis-induced myocardial dysfunction.
Over the last two decades, several studies have questioned the traditional viewing of septic shock as a hyperdynamic process, with preserved myocardial function and decreased peripheral resistance. Up to 60% of septic patients have left and/or right systolic dysfunction, regardless of the presence of baseline heart disease. The diagnostic methods of sepsis-induced myocardial dysfunction, as well as to what extent it conditions in response to treatment, remains a topic of debate.
This Research Topic aims to provide clinicians and researchers an overview on how to consider the presence of myocardial dysfunction in the management of septic patients, through diagnostic assessment and prognostic stratification. It is for this reason, all article types are encouraged.
Sub-topics include, but are not limited to:
1) A thorough evaluation on the role of biomarkers, ultrasound, and other imaging modalities in the diagnosis of sepsis-induced myocardial dysfunction.
2) To evaluate how the presence of sepsis-induced myocardial dysfunction affects the response to the fluid challenge and to vasoactive medications.
3) The use of Dobutamine or other novel inotropes for treatment options in sepsis-induced myocardial dysfunction.
4) Prognostic values of sepsis-induced myocardial dysfunction.
